CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post Sells 1,000 Shares

CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post sold 1,000 shares of the business’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $34.54, for a total value of $34,540.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

CG Oncology Trading Up 3.1 %

Shares of CGON opened at $34.59 on Friday. The business’s 50-day moving average is $35.78 and its 200-day moving average is $34.92. CG Oncology, Inc. has a fifty-two week low of $25.77 and a fifty-two week high of $50.23.

CG Oncology (NASDAQ:CGON) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.06. The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.30 million. CG Oncology had a negative net margin of 10,642.98% and a negative return on equity of 18.97%. Sell-side analysts predict that CG Oncology, Inc. will post -1.31 EPS for the current fiscal year.

Institutional Trading of CG Oncology

Several hedge funds and other institutional investors have recently modified their holdings of the company. Franklin Resources Inc. increased its position in CG Oncology by 8.9% in the 3rd quarter. Franklin Resources Inc. now owns 1,230,193 shares of the company’s stock worth $46,157,000 after purchasing an additional 100,106 shares during the last quarter. Neo Ivy Capital Management bought a new stake in shares of CG Oncology in the 3rd quarter valued at approximately $1,120,000. Geode Capital Management LLC increased its holdings in CG Oncology by 96.2% in the third quarter. Geode Capital Management LLC now owns 1,078,527 shares of the company’s stock worth $40,701,000 after buying an additional 528,749 shares during the last quarter. M&T Bank Corp raised its position in CG Oncology by 55.7% during the third quarter. M&T Bank Corp now owns 16,758 shares of the company’s stock valued at $632,000 after acquiring an additional 5,996 shares in the last quarter. Finally, Barclays PLC grew its position in CG Oncology by 331.1% in the third quarter. Barclays PLC now owns 90,520 shares of the company’s stock worth $3,416,000 after acquiring an additional 69,523 shares in the last quarter. 26.56% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on CGON shares. HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Friday. Bank of America reaffirmed a “buy” rating and set a $65.00 target price on shares of CG Oncology in a research report on Tuesday, October 8th. Roth Mkm started coverage on CG Oncology in a research report on Tuesday, August 27th. They set a “buy” rating and a $65.00 target price on the stock. UBS Group started coverage on CG Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $60.00 target price on the stock. Finally, Roth Capital raised CG Oncology to a “strong-buy” rating in a research report on Tuesday, August 27th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $63.88.

CG Oncology Company Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.